Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma

Table 2 Metastasis-associated in colon cancer 1 mRNA expression and clinical characteristics of hepatocellular carcinoma patients n (%)

Variable	Cases (n = 354)	MACC1 mRNA high expression group	MACC1 mRNA low expression group	P
Gender				0.214
Male	306	157 (88.7)	149 (84.2)
Female	48	20 (11.3)	28 (15.8)
Age (yr)				< 0.001
≥ 55	185	70 (39.5)	115 (65.0)
< 55	169	107 (60.5)	62 (35.0)
Tumor size (cm)				0.087
≥ 3	196	90 (50.8)	106 (59.9)
< 3	158	87 (49.2)	71 (40.1)
Tumor thrombus				0.007
Yes	120	72 (40.7)	48 (27.1)
No	234	105 (59.3)	129 (72.9)
Tumor number				0.356
Single	246	119 (67.2)	127 (71.8)
Multinodular	108	58 (32.8)	50 (28.2)
Stage				0.007
Early-middle	234	105 (59.3)	129 (72.9)
Advanced	120	72 (40.7)	48 (27.1)
Differentiation				< 0.001
High	92	21 (11.9)	71 (40.1)
Moderate	154	92 (52.0)	62 (35.0)
Low	108	64 (36.1)	44 (24.9)
AFP				0.056
≤ 400	184	83 (46.9)	101 (57.1)
> 400	170	94 (53.1)	76 (42.9)
HBeAg				0.190
Positive	136	62 (35.0)	74 (41.8)
Negative	218	115 (65.0)	103 (58.2)
HBV DNA				0.159
Positive	211	99 (55.9)	112 (63.3)
Negative	143	78 (44.1)	65 (36.7)
Child-Pugh				0.326
A	217	104 (58.8)	113 (63.8)
B	137	73 (41.2)	64 (36.2)

HBV: Hepatitis B virus; MACC1: Metastasis-associated in colon cancer 1; AFP: α-fetoprotein; HBeAg: HBV e antigen.